10 Feb Pioglitazone (Actos) Reduced Risk of Secondary Stroke and New Onset of Diabetes
MedicalResearch.com Interview with:
David Spence M.D., FRCPC, FAHA
Professor of Neurology and Clinical Pharmacology
Director, Stroke Prevention & Atherosclerosis Research Centre,
Robarts Research Institute, Western University
London, ON Canada
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The motivation for the study was the chair of the committee that advises the Ontario Drug Benefit which medications to pay for said the IRIS results were not relevant to clinical practice. This because the Insulin Resistance Intervention after Stroke (IRIS) trial reported effects of pioglitazone in patients with stroke or TIA and insulin resistance assessed by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score for insulin resistance.1 ( However, few clinicians measure a HOMA-iR score, so the clinical impact of that trial was limited.
In this study we analyzed the effect of pioglitazone in stroke/TIA patients with prediabetes, which is commonly assessed by clinicians. Prediabetes was defined by the American Diabetes Association: a glycosylated hemoglobin (A1C) of 5.7% to <6.5% (we did not do glucose tolerance tests). We analyzed primarily the results for patients with 80% adherence, but also did an intention-to-treat (ITT) analysis. The reason for focusing on patients with good adherence was that pioglitazone cannot be taken by about 10-20% of patients, because of fluid retention and weight gain (mainly due to fluid retention). (The reasoning was that third party payers would not need to pay for the medication in patients who do not take it.)
In stroke/TIA patients with good adherence, the benefits of pioglitazone were greater than in the original IRIS trial. We found a 40% reduction of stroke/MI, a 33% reduction of stroke, and an 80% reduction of new-onset diabetes, over 5 years. Pioglitazone also improved blood pressure, triglycerides and HDL-cholesterol. As expected, pioglitazone was somewhat less beneficial in the ITT analysis.
Fluid retention can usually be managed by reducing the dose of pioglitazone; even small doses still have a beneficial effect . Also, amiloride has been shown to reduce fluid retention with pioglitazone.
- Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Jr., Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR and Investigators IT. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374:1321-31.
MedicalResearch.com: What should readers take away from your report?
Response: Pioglitazone should be used much more frequently in secondary stroke prevention in patients with prediabetes and diabetes. It should possibly also be used for prevention of new-onset diabetes in patients with prediabetes, even if they haven’t had a stroke or TIA.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Pioglitazone should be studied for prevention of new-onset diabetes in patients with prediabetes, and with metabolic syndrome. Also further study needs to be done about lower doses of pioglitazone, and amiloride for preventing fluid retention with pioglitazone
MedicalResearch.com: Is there anything else you would like to add?
Response: The IRIS trial received pioglitazone and placebo tablets from the manufacturer; the manufacturer had no input into the design, analysis or publication of the trial, but had the right to delay publication for 6 weeks (for patent reasons). I personally have no relevant conflict of interest. My principal interest was to persuade the Ontario Drug Benefit to pay for pioglitazone for secondary stroke prevention in my patients. Sadly, they do not show indications of doing so to date.
Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. Published online February 07, 2019. doi:10.1001/jamaneurol.2019.0079
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.